KARACHI: Pakistan’s polio program on Wednesday confirmed another poliovirus infection from last year, taking the tally of total cases reported in 2024 to 72 amid Islamabad’s attempts to stem the spread of the disease.
Polio is a paralyzing disease that has no cure. Multiple doses of the oral polio vaccine and completion of the routine vaccination schedule for all children under the age of five is essential to provide children high immunity against this terrible disease.
The Regional Reference Laboratory for Polio Eradication at the National Institute of Health confirmed the 72nd case in a female child from the northwestern Dera Ismail Khan district.
“The onset of this case was on December 31, 2024,” the program said in a statement. “D.I. Khan has now reported 11 polio cases in 2024.”
Giving a breakdown of the cases reported in 2024, the program said 27 cases were reported from Balochistan, 22 from Khyber Pakhtunkhwa, 21 from Sindh, and one each from Punjab and Islamabad.
Pakistan, along with neighboring Afghanistan, remains the last polio-endemic country in the world. In the early 1990s, Pakistan reported around 20,000 cases annually but in 2018 the number dropped to eight cases. Six cases were reported in 2023 and only one in 2021.
Pakistan’s polio eradication efforts have met several challenges in recent years, including attacks by militants and misinformation by religious hard-liners.
The Pakistan polio program is scheduled to hold the country’s first nationwide vaccination drive of this year from Feb. 3 till Feb. 9.
“It is crucial for parents to ensure vaccination for all their children under the age of five to keep them protected,” it said.
Pakistan polio program says 72 cases reported in 2024
Short Url
https://arab.news/8638a
Pakistan polio program says 72 cases reported in 2024
- Seventy-second polio case reported in female child from northwestern Dera Ismail Khan district
- Pakistan polio program is scheduled to hold first nationwide vaccination drive of 2025 from Feb. 3
© 2026 SAUDI RESEARCH & PUBLISHING COMPANY, All Rights Reserved And subject to Terms of Use Agreement.










